See more : Waldencast plc (WALD) Income Statement Analysis – Financial Results
Complete financial analysis of Kinnate Biopharma Inc. (KNTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kinnate Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Black Diamond Resources Tbk (COAL.JK) Income Statement Analysis – Financial Results
- Harvest Capital Credit Corporation 6.125% Notes due 2022 (HCAPZ) Income Statement Analysis – Financial Results
- Thunder Mountain Gold, Inc. (THM.V) Income Statement Analysis – Financial Results
- Sumou Real Estate Company (9511.SR) Income Statement Analysis – Financial Results
- McGrath RentCorp (MGRC) Income Statement Analysis – Financial Results
Kinnate Biopharma Inc. (KNTE)
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 799.00K | 604.00K | 123.00K | 83.00K | 0.00 | 0.00 |
| Gross Profit | -799.00K | -604.00K | -123.00K | -83.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.77M | 88.15M | 67.17M | 29.24M | 8.96M | 5.68M |
| General & Administrative | 0.00 | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.44M | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Other Expenses | 0.00 | 2.25M | 348.00K | -5.00K | 0.00 | 0.00 |
| Operating Expenses | 118.21M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Cost & Expenses | 119.01M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Interest Income | 8.53M | 0.00 | 348.00K | 245.00K | 43.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 799.00K | 604.00K | 123.00K | 83.00K | 171.86K | 161.14K |
| EBITDA | -118.21M | -117.92M | -89.99M | -35.92M | -12.01M | -7.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -119.01M | -118.52M | -90.11M | -36.00M | -12.01M | -7.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.36M | 2.25M | 348.00K | 240.00K | 43.00K | 0.00 |
| Income Before Tax | -112.65M | -116.27M | -89.76M | -35.76M | -11.97M | -7.63M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.25M | -348.00K | -328.00K | -43.00K | 0.00 |
| Net Income | -112.65M | -114.02M | -89.42M | -35.43M | -11.93M | -7.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| Weighted Avg Shares Out | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
| Weighted Avg Shares Out (Dil) | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA...
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
SAN FRANCISCO and SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of...
Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting
SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that data from pre-clinical studies of its RAF...
KNTE Stock Price Increased 7.37%: Why It Happened
The stock price of Kinnate Biopharma Inc (NASDAQ: KNTE) increased by 7.37%. This is why it happened.
Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results
Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it...
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Nima...
Why These 4 Health Care Stocks Are Moving Today
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing...
Why SVB Leerink Is Bullish On Kinnate Biopharma
Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in an initial public offering priced at $20 per share. The Kinnate Biopharma Analyst: Following the end of the...
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the closing of...
Source: https://incomestatements.info
Category: Stock Reports